Assess nicotine dependence severity with the 6-item Fagerström Test. Get FTND score, dependence level, pharmacotherapy recommendations, and cessation treatment guidance.
The Fagerström Test for Nicotine Dependence (FTND) Calculator implements the standard 6-item validated questionnaire for assessing the intensity of physical nicotine dependence in cigarette smokers. Originally developed by Karl-Olov Fagerström in 1978 as the Fagerström Tolerance Questionnaire (FTQ), it was revised to the current FTND form by Heatherton et al. in 1991 to better measure physical dependence rather than overall smoking behavior.
The FTND score (0–10) strongly predicts difficulty quitting, withdrawal severity, and the need for pharmacotherapy. Two items are particularly predictive: time to first cigarette after waking (the strongest single predictor of dependence) and number of cigarettes per day. These two items form the Heaviness of Smoking Index (HSI), a validated 2-item brief alternative used when the full FTND is impractical.
Higher FTND scores indicate greater physical dependence and stronger need for pharmacological cessation aids. Smokers with scores ≥7 have approximately half the quit rate of those with scores ≤3 without pharmacotherapy, but this gap narrows significantly with appropriate treatment. The FTND guides treatment intensity: low-dependence smokers may succeed with behavioral support alone or simple NRT, while highly dependent smokers benefit most from varenicline or combination NRT plus intensive counseling.
Nicotine dependence severity directly impacts quit success rates and treatment selection. Highly dependent smokers who attempt to quit without adequate pharmacotherapy have very low success rates (~3–5%). The FTND identifies these at-risk individuals so treatment can be appropriately intensified. It also sets realistic expectations and helps clinicians tailor the cessation approach.
FTND Total = Sum of 6 items Q1: Time to first cigarette: ≤5 min=3, 6–30 min=2, 31–60 min=1, >60 min=0 Q2: Difficulty refraining: Yes=1, No=0 Q3: Hardest to give up: First morning=1, Other=0 Q4: Cigarettes/day: ≤10=0, 11–20=1, 21–30=2, ≥31=3 Q5: Morning smoking heavier: Yes=1, No=0 Q6: Smoking when ill: Yes=1, No=0 HSI (Heaviness of Smoking Index) = Q1 + Q4 (range 0–6) Score range: 0–10
Result: FTND Score: 8/10 — High Dependence. Varenicline recommended + intensive counseling.
Total score: 2+1+1+2+1+1 = 8. HSI: 2+2 = 4/6. This indicates high physical nicotine dependence. The early time to first cigarette and continued smoking when ill are markers of strong physical dependence. Varenicline is the preferred pharmacotherapy, combined with at least 4 counseling sessions. Combination NRT (21mg patch + gum/lozenge) is an effective alternative.
The original Fagerström Tolerance Questionnaire (FTQ, 1978) contained 8 items and measured both behavioral and physical dependence. Heatherton et al. (1991) revised it to the FTND by removing two items with low item-total correlations (inhaling depth and nicotine/tar yield) and modifying the scoring of two others. The FTND has been validated against biochemical markers (cotinine levels, exhaled CO), withdrawal severity, and cessation outcomes in dozens of studies across diverse populations.
A Cochrane review of 150+ trials established the hierarchy: Varenicline (OR 2.88 vs. placebo) > Combination NRT (OR 2.73) > Single NRT (OR 1.84) ≈ Bupropion (OR 1.82). Combining any medication with behavioral counseling (≥4 sessions) adds ~50% to the quit rate. Cost-effectiveness analyses consistently show cessation treatments are among the most cost-effective medical interventions available. Even modest improvements in quit rates produce significant health benefits given the enormous health burden of smoking.
The FTND has limitations: it doesn't assess psychological/social dependence, behavioral habits, or motivation to quit. Complementary tools include: the Cigarette Dependence Scale (CDS-12, broader dependence measure), Stages of Change assessment (readiness to quit), Wisconsin Inventory of Smoking Dependence Motives (WISDM, detailed motivational profile), and the Glover-Nilsson Smoking Behavioral Questionnaire (behavioral habit strength). A comprehensive cessation assessment integrates multiple dimensions beyond physical dependence.
The most effective approach combines pharmacotherapy with behavioral support (counseling, quitline, support group). Varenicline (Chantix) has the highest single-agent quit rate (~33% at 6 months). Combination NRT (patch + short-acting form like gum or lozenge) is similarly effective. Adding behavioral counseling (at least 4 sessions) approximately doubles the quit rate regardless of medication choice. For most smokers, especially those with FTND ≥5, medication plus counseling is recommended.
The HSI is a 2-item subscale using only Q1 (time to first cigarette) and Q4 (cigarettes per day). It ranges from 0–6 and has been validated as a brief alternative to the full FTND. HSI ≥4 indicates heavy smoking/high dependence. It's useful in busy clinical settings where administering the full 6-item FTND isn't practical, and it predicts cessation outcomes nearly as well as the full scale.
Smoking within 30 minutes of waking indicates that overnight nicotine withdrawal symptoms are strong enough to drive immediate smoking behavior. This reflects high receptor occupancy and neuroadaptation — the brain "needs" nicotine to function normally. Smokers who smoke within 5 minutes of waking have significantly lower quit rates without pharmacotherapy and experience more severe withdrawal symptoms (irritability, anxiety, difficulty concentrating, cravings).
Withdrawal symptoms typically: begin within 2–4 hours of last cigarette, peak at 2–3 days, and gradually improve over 2–4 weeks. Common symptoms: intense cravings (can persist for months), irritability, anxiety, difficulty concentrating, restlessness, increased appetite, insomnia, and depressed mood. Pharmacotherapy significantly reduces the severity of these symptoms. The acute phase is hardest, but many quitters report lingering cravings for months, triggered by situations previously associated with smoking.
E-cigarettes are not FDA-approved cessation aids, and evidence is mixed. Some trials show higher quit rates than NRT, while others show no benefit. Concerns include: maintaining nicotine addiction (switching rather than quitting), unknown long-term health effects, dual use (vaping + smoking), and youth initiation. Major medical organizations (ACS, AHA) acknowledge e-cigarettes may be less harmful than cigarettes but don't recommend them as first-line cessation tools. FDA-approved medications (varenicline, NRT, bupropion) remain the standard of care.
Even low-dependence smokers (FTND 0–2) benefit from pharmacotherapy — NRT approximately doubles quit rates across all dependence levels. However, low-dependence smokers also have reasonable quit rates with behavioral support alone (~14–20%). The decision depends on patient preference, prior quit attempts (those who've failed behavioral-only approaches should try medication), and clinical judgment. Brief NRT (gum, lozenge) is often sufficient for low-dependence smokers who opt for pharmacotherapy.